Mifepristone

Generic Name: Mifepristone

Brand Names: Korlym, Mifegymiso

Drug Type: Small Molecule

Chemical Formula: C_₂₉H_₃₅NO_₂

CAS Number: 84371-65-3

Unique Ingredient Identifier: 320T6RNW1F

Background: Mifepristone is a progestational and glucocorticoid hormone antagonist. Its inhibition of progesterone induces bleeding during the luteal phase and in early pregnancy by releasing endogenous prostaglandins from the endometrium or decidua. As a glucocorticoid receptor antagonist, the drug has been used to treat hypercortisolism in patients with nonpituitary cushing syndrome. The two marketed forms of mifepristone are Mifeprex® (mifepristone 200mg) and Korlym™ (mifepristone 300mg). Currently under investigation for use in psychotic depression (phase 3 trials).

Indication: For the medical termination of intrauterine pregnancy through 49 days' pregnancy. Also indicated to control hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and are not candidates for surgery or have had unsuccessful surgery.

Associated Conditions: Hyperglycemia

Associated Therapies: Medically induced abortion

Clinical Trials

Cervical Preparation With Mifepristone Prior to Osmotic Dilators

Phase 2

Terminated

Conditions: Second Trimester Abortion

Interventions: Drug: Mifepristone 200 MG
Drug: Placebo Oral Tablet

First Posted Date: 2018-10-22

Last Posted Date: 2022-06-08

Lead Sponsor: University of California, Davis

Target Recruit Count: 44

Registration Number: NCT03714880

Locations: 🇺🇸
UC Davis Department of Obstetrics and Gynecology, Sacramento, California, United States

Evaluation of Therapeutic Effect and Safety of Mifepristone in the Treatment of Adenomyosis

Phase 2

Completed

Conditions: Adenomyosis

Interventions: Drug: Placebo
Drug: Mifepristone

First Posted Date: 2018-05-09

Last Posted Date: 2019-10-03

Lead Sponsor: xinmei zhang

Target Recruit Count: 134

Registration Number: NCT03520439

Locations: 🇨🇳
Women's Hospital of Zhejiang Medical University, Hangzhou, Zhejiang, China

CORT125134 Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD)

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Matching Placebo of CORT125134
Drug: CORT125134
Drug: Mifepristone
Drug: Prednisone
Drug: Glucose

First Posted Date: 2018-04-26

Last Posted Date: 2019-08-09

Lead Sponsor: Corcept Therapeutics

Target Recruit Count: 130

Registration Number: NCT03508635

Locations: 🇬🇧
Quotient Clinical, Nottingham, Nottinghamshire, United Kingdom

Outpatient Service for Mid-trimester Termination of Pregnancy

Phase 4

Completed

Conditions: Abortion in Second Trimester

Interventions: Drug: Mifepristone + Misoprostol

First Posted Date: 2017-11-17

Last Posted Date: 2019-04-26

Lead Sponsor: Gynuity Health Projects

Target Recruit Count: 230

Registration Number: NCT03346629

Locations: 🇳🇵
Kathmandu Model Hospital, Kathmandu, Nepal
🇳🇵
Kathmandu Medical College, Kathmandu, Nepal
🇳🇵
KIST Medical College, Teaching Hospital, Imadol, Lalitpur, Nepal

Medication Abortion Via Pharmacy Dispensing

Phase 4

Completed

Conditions: Pregnancy Related
Abortion Early

Interventions: Other: Training on mifepristone dispensing
Drug: Mifepristone

First Posted Date: 2017-10-25

Last Posted Date: 2021-07-12

Lead Sponsor: Daniel Grossman

Target Recruit Count: 326

Registration Number: NCT03320057

Locations: 🇺🇸
Obstetrics and Gynecology Family Planning Clinic at University of California Davis, Sacramento, California, United States
🇺🇸
Planned Parenthood Great Northwest, Hawai'i, Alaska, Indiana, Kentucky, Tacoma, Washington, United States
🇺🇸
Women's Health Services at University of California San Diego, San Diego, California, United States

and more 3 locations